Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cancer Killing Platforms. Candel and IceCure. I only bought a 5000 shares of $CADL at .88 sold half at 9.00 riding 2500 shares.. I'm accumulating shares of IceCure Literally has a cure rate for early breast cancer patients with a success rate at 97% with 5 year independent follow up DATA . Even more impressive is the late stage breast cancer data just came out with a year follow up with 92.5% success rate treating tumors twice the size as the ones treated in the early breast cancer patients. Cryoblast is seeing amazing results in Lung, Liver and Kidney Cancer. approved in 15 countries including Brazil, China and many EU countries. Insurance companies are on board and patients are using the technology in the USA but have to pay out of pocket until FDA approval. The minimally invasive medical space is growing companies like $PLSE went from 50 million market to a Billion in the last two years Pulse Biosciences and IceCure $ICCM have very cutting edge technology with better quicker results than surgery with procedures being done with local anesthetic in a in a doctors office being able to go home with in a few hours pretty remarkable. IceCure will see tremendous growth and one of the Richest families in Asia the Lee family Victor Lee an a early invester in Tencent owns 52% of IceCure shares.
$CADL.
Remember them buying up 450k shares a second after the readout was released on May23 all the way into high 16s.
sooner or later, the data will speak again and everyone will have to listen to whats being said.
only 1.5 mil short
CADL................................a/h...................$$$$$$$$$$$$$$$$$$$$$$$$$$$
Short squeeze coming soon, mm have been borrowing my shares.
agree. mcap should be 1bln $+++.
institutions are waiting on the bid- then do the lifting on liquidity event.
LOTS of retail antihero-themed traders are short. Weak line of defense.
I cant believe this is still sitting at 5. The orphan designation for pancreatic itself is huge. Makes no sense. Imo
$CADL GROUNDBREAKING data... never before.
see latest presentation regarding pending data in nsclc and CRC
Check Paul Peter Tak vita... Its a home run
Good job, she’s got legs. Maybe it will cool off in the morning for another possible dip then it’s chart making time. Shorts are staying away from this one as the potential for blue sky breakout is very good.
$cadl. The next few hours should be engaging to say the least
Looking for a push towards previous double top of 11.30’s and then a breakout through to blue skies
Sure is! Added some $cadl $6.50's here
She's got that look!
Chart is building nicely ..
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Thats it just goes up news and then sell on news?? There is no holding here??
Could be a blue sky breakout if all these fundamentals line up. Big potential here.
New here, do you have a link please? Thank you
I am Getting Ready for tomorrow's Blast-off Opening at $15+, as we could possibly see news at 8:30AM about a 'Private Placement' of maybe 5M Common shares 'Unit's @$15.00/share Plus each Warrant in the unit exercisable at $15/common share, upon dosing of the 1st Patient in the Phase 3 trial...with total 'Net proceeds' of around $140M giving Runway to EOY 2026!
This stock was 'walked down' in PPS Friday afternoon. I am fully loaded. This is going to move up north of $30+ next two months. It has catalyst "READOUTs' coming up next two months and then into 4rth Q. Do not sell out for peanuts profits if you want to make massive gains, just HODL it till EOY 2024.Also, very possible it could be taken out anytime...GLTA!
All that volume and only up 3% lol??
ALERT- Cash Position: Cash and cash equivalents as of December 31, 2023 were $35.4 million, as compared to $70.1 million as of December 31, 2022. Based on current plans and assumptions, the Company expects that its existing cash and cash equivalents will be sufficient to fund its current operating plan into the fourth quarter of 2024
Phase 2 topline data for CAN-2409 in low-to-intermediate-risk, localized, non-metastatic prostate cancer expected in Q4 2024
Phase 3 topline data for CAN-2409 in localized intermediate/high-risk prostate cancer expected in Q4 2024
The dump here when the computers doing the trading are turned off is going to be brutal.
you are very good at taking risk, that is why u are so rich. what about if it dips at 4a.
did you catch it early?
CADL: Easiest money of the week, that's for sure, Capt. Tim!!! (And I'm still holding it all.)
nice try****so far almost 500%*****
#CADL 🔥 insane run today! What about tomorrow? $cadl
Very true Monk, if one doesn't have a plan, most likely will lose it all.
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
97
|
Created
|
09/22/21
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |